Affordable Access

deepdyve-link deepdyve-link
Publisher Website

High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.

Authors
  • Kamel, Sarah
  • O'Connor, Shaun
  • Lee, Newton
  • Filshie, Robin
  • Nandurkar, Harshal
  • Tam, Constantine S
Type
Published Article
Journal
Leukemia & Lymphoma
Publisher
Informa UK (Taylor & Francis)
Publication Date
May 01, 2010
Volume
51
Issue
5
Pages
797–801
Identifiers
DOI: 10.3109/10428191003699860
PMID: 20367135
Source
Medline
License
Unknown

Abstract

The risk of infection with Pneumocystis jirovecii pneumonia (PCP) in patients undergoing chemotherapy is closely related to the intensity of corticosteroid exposure. PCP is uncommon with classical (3-weekly) R-CHOP, but the risk may be higher with biweekly R-CHOP (R-CHOP-14) due to the increased frequency of prednisolone pulses. Among 47 consecutive patients treated with R-CHOP-14 at our institution, five (11%) developed microbiologically proven PCP, with a further two (4%) having classical clinical and radiological features of PCP, but without microbiological confirmation. None of these patients were HIV-positive or had additional risk factors for PCP. Our experience suggests that PCP prophylaxis should be considered in institutions using R-CHOP-14 for the treatment of patients with aggressive lymphomas.

Report this publication

Statistics

Seen <100 times